PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Higher upside than AXSM's upside of 56.00%.
Buy
Equal to AXSM's analyst recommendation of Buy.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-100.00%
Worse than AXSM's revenue growth rate of 25.00%.
-37.43M
Worse than AXSM's ebitda of 79.05M.
100.00%
Better than AXSM's ebitda margin of 23.37%.
-38.24M
Worse than AXSM's ebit of 77.34M.
100.00%
Better than AXSM's ebit margin of 22.87%.
811.00K
Better than AXSM's depreciation of 212.18M.
72.90M
Worse than AXSM's total cash of 338.25M.
100.00%
Equal to AXSM's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than AXSM's receivables as percentage of revenue of 82.08%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than AXSM's inventories as percentage of revenue of 62.85%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than AXSM's payables as percentage of revenue of 78.44%.
-11.00K
Worse than AXSM's capital expenditure of -1.09M.
100.00%
Worse than AXSM's capex as percentage of revenue of -0.32%.
4.99%
Better than AXSM's weighted average cost of capital (wacc) of 9.92%.
5.02%
Better than AXSM's cost of equity of 10.17%.
4.08%
Better than AXSM's cost of debt of 4.26%.
-0.23
Better than AXSM's beta of 1.25.
30.07M
Better than AXSM's diluted shares outstanding of 45.43M.
1.57M
Better than AXSM's total debt of 186.37M.
49.31M
Worse than AXSM's total equity of 4.18B.
50.89M
Worse than AXSM's total capital of 4.36B.
3.09%
Better than AXSM's debt weighting of 4.27%.
96.91%
Better than AXSM's equity weighting of 95.73%.
-38.24M
Worse than AXSM's ebiat of 77.34M.
-45.40M
Worse than AXSM's unlevered free cash flow of 132.82M.
2.00%
Equal to AXSM's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than AXSM's net debt of -199.82M.
71.33M
Worse than AXSM's equity value of 6.33B.
2.37
Worse than AXSM's equity value per share of 139.31.
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
Worse than AXSM's estimated revenue of 646.74M.
-1.93M
Worse than AXSM's estimated ebitda of 151.15M.
-1.38
Better than AXSM's estimated eps of -1.51.
-41.62M
Better than AXSM's estimated net income of -104.49M.
-1.93M
Worse than AXSM's estimated ebit of 147.88M.
358.54M
Better than AXSM's estimated sg&a expense of 954.17M.